Glimbetic M1 Forte Tablet is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The synergistic effect of these two agents helps achieve better blood glucose regulation in patients inadequately controlled by diet and exercise alone or monotherapy. Glimbetic M1 Forte is prescribed as part of a comprehensive diabetes management plan, including diet modification and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and potential hypoglycemia due to Glimepiride. Regular monitoring of blood glucose levels, renal function, and periodic assessment of glycemic control is recommended during therapy. Dose adjustments may be necessary based on therapeutic response and tolerance. This combination tablet offers an effective and convenient option for optimizing glycemic control in type 2 diabetes patients.